Received Feb 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 24M7E | IM / RA |
patient had received two shots of Shingrix, but they were more; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 64-year-old male patient who received Herpes zoster (Shingrix) (batch number 24M7E, expiry date 02-APR-2026) for prophylaxis. Previously administered products included Shingrix (1st dose received on 22-NOV-2021). On 03-JAN-2025, the patient received the 2nd dose of Shingrix (intramuscular, right deltoid). On 03-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient had received two shots of Shingrix, but they were more). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 21-FEB-2025 Reporter did not had access saw this in registry first dose was not administered at their pharmacy. The reporter stated that although the pharmacy has email it was for internal use only. She reported to the GRC on 21 February 2025 that a patient had received a shots of Shingrix, but they were more than 6 months apart. Reporter did not have access to the lot number for dose #1 which was given at a different facility in 2021. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.